Genoa. The results of the SRG Performance Evaluation System, coordinated by the Management and Healthcare Laboratory (MeS) at the Sant’Anna School of Advanced Studies of Pisa for the year 2021, were presented today in Perugia. The regions voluntarily join the Best Performance Evaluation System Italian companies, which undertake to share monitoring indicators and related standards in order to identify best practices to be exploited, and areas with potential margins for improvement to direct and activate subsequent actions.
Regarding the results for the Liguria region for the year 2021, despite the persistent Covid-19 emergency, the region generally recorded good results or in line with the average for the following areas: prevention (vaccination coverage, effectiveness / efficiency of prevention, hygiene and safety services in the workplace), efficacy (medical hospitalization, pharmaceutical prescriptions, health costs per capita), process quality and quality / appropriateness of supervised clinical care courses (including maternal infantile and oncology), pharmaceutical field (general appropriateness and opioid consumption), emergency-hurry-way.
It is a monitoring – explains the President and Councilor for Health of the Liguria region – which shows how the Ligurian health system has many areas of performance among the best in Italy. So much so that only the best performing regions voluntarily participate in this evaluation system. It should be emphasized in particular that among the indicators for which Liguria has positive results are the indicators for the emergency system: in this context, the data describing the ability to respond from the citizen’s report and leading to the first treatment, on arrival of ambulances and access to emergency rooms. This indicator for the Liguria region is higher than the average of the best performing regions and is further improving.
“The identification of regional and corporate strengths and weaknesses – explained Filippo Ansaldi General Manager of Alisa – stems from an internal comparison with the regions that follow the evaluation system, among which regions historically record the best results in the delivery of essential levels This means that Liguria is fully among these realities, and also thanks to this monitoring it is possible to identify where it is possible to intervene where there is room for improvement “.
In addition to the Liguria region, 11 other regions / autonomous provinces join voluntarily: Tuscany, Lombardy, Veneto, Piedmont, Friuli Venezia Giulia, PA Bolzano, PA Trento, Puglia, Marche, Umbria, Basilicata. The evaluation system consists of over 450 indicators, of which about 150 are included as “evaluation” measures and the rest are called “observation indicators”. The evaluation indicators are grouped in some summary indices reported on the so-called “Target”. The system is based on an assessment of the different areas and health courses, which allows to elaborate on the individual aspects of performance: efficiency, effectiveness, appropriateness, etc.) and at the same time request a joint analysis and reading.
For the year 2021, margins for improvement are identified, albeit in the presence of positive trends compared to 2020, for some areas: efficacy in surgical admissions (improvement), diabetic footing, diagnostically appropriate, home care, drug adherence, voluntary discharge (improvement), screening activities (improvement) ) and waiting times for cancer surgery. For these last two areas, the Ligurian region has drawn up a specific plan to improve the offer through the RESTART Health program, implemented from the fourth quarter of 2021, and the regional operational plan for the restoration of waiting lists, which will see full implementation and effect in 2022.
Regarding the resilience indicators, identified to support the regions in relaunching the activities of the SSR at the end of the Covid-19 emergency, for the year 2021, in the light of positive results or in line with the average in terms of time-dependent networks and cardio cycles, margins for improvement are identified, despite the positive 2020-2021 trends, for the pharmaceutical and oncology area (improvement) for the follow-up and screening areas (both in improvement). As previously highlighted, the RESTART program and the regional operational plan for restoring waiting lists have been developed and implemented to improve screening and oncology routes as well as for the area of specialist follow-ups, which will see full implementation and impact during 2022.